The full-length molecule, and the one the actual research concerns — a distinction routinely blurred by vendors selling “TB-500”. It is among the most abundant proteins in most cells, binding monomeric G-actin and regulating the polymerisation that drives cell migration. Its effects on angiogenesis, keratinocyte migration and inflammation follow from that role.
Reached genuine clinical trials — phase 2 in dry eye disease, venous stasis ulcers and epidermolysis bullosa — which is more than TB-500 can claim. Results were insufficient to carry it to approval. Extensive preclinical work in cardiac and corneal repair.
Not FDA-approved. Development discontinued. Prohibited in sport (WADA S0).
Trial safety data exist at studied exposures. The pro-angiogenic mechanism carries the same unresolved theoretical concern as BPC-157 — an agent that promotes vessel growth does not choose which tissue benefits.
Forge Bioenergy does not publish dosing, reconstitution, or administration protocols for any peptide. See our editorial policy for why. If you are considering any substance on this page, that conversation belongs with a licensed physician.
Regulatory status changes. This page reflects our reading of public sources as of July 2026 and should be independently verified before it is relied upon.